Patents by Inventor James Meador, III

James Meador, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158508
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Application
    Filed: July 13, 2023
    Publication date: May 16, 2024
    Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
  • Publication number: 20230374062
    Abstract: Disclosed herein are methods galatosylating IgG antibodies, methods of preparing hypersialylated (hsIgG), e.g., using immobilized ?1,4-Galactosyltransferase I (?4GalT1), as well as polypeptides comprising ?1,4-Galactosyltransferase I (?4GalT1) bound to a solid support and compositions comprising the same.
    Type: Application
    Filed: March 4, 2021
    Publication date: November 23, 2023
    Inventors: Naveen Bhatnagar, James Meador, III
  • Publication number: 20230303984
    Abstract: Described herein are fusion proteins, e.g., fusion proteins comprising enzymatically active portion(s) of ST6Gall or B4GalT1 as well as methods for producing them, nucleic acid molecule(s) encoding the fusion protein(s), vectors comprising the nucleic acid molecule(s), and host cell(s) comprising the vector(s). Also described herein are methods of sialyating immunoglobulin G (IgG) antibodies.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 28, 2023
    Inventors: James Meador, III, Sandra Freitas Pavao Sipsey, Amy Medeiros, Srishti Gurnani
  • Patent number: 11732047
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: August 22, 2023
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
  • Publication number: 20230049725
    Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.
    Type: Application
    Filed: April 28, 2022
    Publication date: February 16, 2023
    Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
  • Patent number: 11345751
    Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 31, 2022
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
  • Publication number: 20220153833
    Abstract: The present invention relates to methods of using biologically active Fc domain-containing therapeutic constructs (Fc constructs) to induce immune cell activation of the immune response in a subject, and for example, to treat diseases such as cancers and infections in a subject. Such Fc constructs may include 5 or more Fc domains.
    Type: Application
    Filed: March 2, 2017
    Publication date: May 19, 2022
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky, Birgit C. Schultes
  • Publication number: 20220033499
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: August 20, 2021
    Publication date: February 3, 2022
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Patent number: 11124573
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: September 21, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20210238275
    Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.
    Type: Application
    Filed: July 31, 2017
    Publication date: August 5, 2021
    Inventors: Leona E. Ling, Sucharita Roy, Nathaniel Washburn, Marilyn Kehry, David J. King, Anthony Manning, James Meador, III, Jan Hillson
  • Publication number: 20200299382
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 24, 2020
    Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
  • Patent number: 10676526
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 9, 2020
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
  • Patent number: 10377832
    Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 13, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
  • Publication number: 20190225688
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 25, 2019
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Patent number: 10239944
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Publication number: 20180016334
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Application
    Filed: January 29, 2016
    Publication date: January 18, 2018
    Inventors: Marilyn KEHRY, David J. KING, Leona E. LING, James MEADOR, III, Sucharita ROY, Anthony MANNING
  • Publication number: 20170349662
    Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
    Type: Application
    Filed: April 25, 2017
    Publication date: December 7, 2017
    Inventors: Nathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
  • Patent number: 9663581
    Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 30, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
  • Publication number: 20170066826
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 9, 2017
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. BOSQUES, James S. HUSTON, Jonathan C. LANSING, Leona E. LING, James MEADOR, III, Daniel ORTIZ, Laura RUTITZKY, Birgit C. SCHULTES
  • Publication number: 20160229913
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: April 28, 2016
    Publication date: August 11, 2016
    Inventors: Carlos J. BOSQUES, James S. HUSTON, Jonathan C. LANSING, Leona E. LING, James MEADOR, III, Daniel ORTIZ, Laura RUTITZKY, Birgit C. SCHULTES